Larvol Delta - Realworld-effectiveness-and-safety-of-bimekizumab-in-moderatetosevere-hidradenitis-suppurativa-Primary-outcomes-at-52-weeks-with-extended-followup-to-104-weeks

Bimzelx (bimekizumab-bkzx) - UCB

https://pagv3.virtual-meeting.org/eadv/eadvcongress2026/en-GB/pag/presentation/62173

Carmen García Moronta

Aug 6, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next